Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $65.00 at Chardan Capital

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price objective boosted by research analysts at Chardan Capital from $29.00 to $65.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 355.34% from the stock’s previous close.

EYPT has been the topic of several other reports. Guggenheim reaffirmed a “buy” rating and set a $68.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Citigroup boosted their price objective on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, March 9th. HC Wainwright upped their price objective on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada decreased their target price on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $43.83.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT opened at $14.28 on Wednesday. The business’s fifty day moving average price is $13.20 and its two-hundred day moving average price is $14.53. The stock has a market cap of $1.20 billion, a PE ratio of -4.08 and a beta of 1.72. Eyepoint Pharmaceuticals has a one year low of $8.95 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative net margin of 3,566.63% and a negative return on equity of 110.54%. As a group, equities research analysts predict that Eyepoint Pharmaceuticals will post -3.09 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the firm’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cyndeo Wealth Partners LLC boosted its position in shares of Eyepoint Pharmaceuticals by 3.4% in the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company’s stock worth $420,000 after acquiring an additional 760 shares during the last quarter. California State Teachers Retirement System increased its position in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the last quarter. RWC Asset Management LLP raised its stake in Eyepoint Pharmaceuticals by 6.4% during the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company’s stock worth $315,000 after purchasing an additional 1,040 shares during the period. MCF Advisors LLC raised its stake in Eyepoint Pharmaceuticals by 8.3% during the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company’s stock worth $273,000 after purchasing an additional 1,149 shares during the period. Finally, Raymond James Financial Inc. raised its stake in Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after purchasing an additional 1,177 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.